Our study suggests that C6orf120 influences not only the immune landscape of LIHC but also the regulation of tumor angiogenesis, indicating that C6orf120 could be a strategic target for an integrated approach to cancer therapy that encompasses both targeted therapy and immunotherapy. The gene discussed is C6orf120; the disease is neoplasm.